NeuroMetrix, Inc. (NURO)

$2.97

+0.02 (+0.68%)
Rating:
Recommendation:
Buy
Symbol NURO
Price $2.97
Beta 2.570
Volume Avg. 0.09M
Market Cap 21.178M
Shares () -
52 Week Range 2.7-11.85
1y Target Est -
DCF Unlevered NURO DCF ->
DCF Levered NURO LDCF ->
ROE -16.02% Sell
ROA -15.08% Sell
Operating Margin -
Debt / Equity 7.89% Neutral
P/E -
P/B 0.89 Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest NURO news


Dr. Shai Gozani
Healthcare
Medical Devices
NASDAQ Capital Market

NeuroMetrix, Inc., a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.